Blood level of B and CD4+ lymphocytes measured before induction of an experimental tumor in rats predicts tumor progression and survival

Cancer Epidemiology Biomarkers and Prevention

Volumn 9, Issue 6, 2000, Pages 609-617

  Demetrikopoulos, Melissa K ^a,c   Goldfarb, Ronald H ^d   Zhang, Zhao Bin ^c   Weiss, Jay M ^b,c  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Emory West Campus ^*  (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER; CANCER SURVIVAL; CARCINOGENESIS; FEMALE; LYMPHOCYTE COUNT; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

ADENOCARCINOMA; ANIMALS; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; FEMALE; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; NEOPLASM METASTASIS; PROGNOSIS; RATS; RATS, INBRED STRAINS; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED;

EID: 0034130338     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Gorelik, E., Wiltrout, R. H., Okumura, K., Habu, S., and Herberman, R. B. Role of NK cells in the control of metastatic spread and growth of tumor cells in mice. Int. J. Cancer, 30: 107-112, 1982.
2. Barlozzari, T., Leonhardt, J., Wiltrout, R. H., Herberman, R. B., and Reynolds, C. W. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J. Immunol., 134: 2783-2789, 1985.
3. Quan, N., Zhang, Z., Demetrikopoulos, M. K., Kitson, R. P., Chambers, W. H., Goldfarb, R. H., and Weiss, J. M. Evidence for involvement of B lymphocytes in the surveillance of lung metastasis in the rat. Cancer Res., 59: 1080-1089, 1999.
4. Yuhas, J. M. Role of T and B lymphocytes in the development and growth of experimental metastases. In: S. B. Day et al. (eds.), Cancer Invasion and Metastasis: Biologic Mechanisms and Therapy, pp. 347-352. New York: Raven Press, 1977.
5. Guo, Y., Wu, M., Chen, H., Wang, X., Liu, G., Li, G., Ma, J., and Sy, M-S. Effective tumor vaccine generated by fusion of hepatoma cells with activated B cells. Science (Washington DC), 263: 518-520, 1994.
6. Quin, Z., and Blankenstein, T. Tumor growth inhibition mediated by lymphotoxin: evidence of B lymphocyte involvement in the antitumor response. Cancer Res., 55: 4747-4751, 1995.
7. Reisfeld, R. A., Gillies, S. D., Mendelsohn, J., Varki, N. M., and Becker, J. C. Involvement of B lymphocytes in the growth inhibition of human pulmonary melanoma metastases in athymic nu/nu mice by an antibody-lymphotoxin fusion protein. Cancer Res., 56: 1707-1712, 1996.
8. Marquet, R. L., Westbroek, D. L., and Jeekel, J. Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int. J. Cancer, 33: 689-692, 1984.
9. Wexler, H. Accurate identification of experimental pulmonary metastases. J. Natl. Cancer Inst., 36: 641-645, 1966.
10. Yuan, D., Koh, C. Y., and Wilder, J. A. Interactions between B lymphocytes and NK cells. FASEB J., 8: 1012-1018, 1994.
11. Mengel, J., Dare, L., Dare, G. M., Delgado, M., Nomizo, A., Silva, J. S., and Campos-Neto, A. An activated murine B cell lymphoma line (A-20) produces a factor-like activity which is functionally related to human natural killer cell stimulatory factor. Eur. J. Immunol., 22: 3173-3178, 1992.
12. Bennink, J. R., Anderson, R., Bacik, I., Cox, J., Day, P., Deng, Y., Lapham, C., Link, H., Rustav, G., and Yewdell, J. W. Antigen processing: where tumor-specific T-cell responses begin. J. Immunother., 14: 202-208, 1993.
13. Peoples, G. E., Goedegebuure, P. S., Andrews, J. V. R., Schoof, D. D., and Eberlein, T. J. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J. Immunother., 151: 5481-5491, 1993.
14. Pernis, B., and Weber, D. A. Cell biology of antigen presentation by B lymphocytes. Contrib. Microbiol. Immunol., 11: 27-42, 1989.
15. Lee, Y-T. N. Peripheral lymphocyte count and subpopulations of T and B lymphocytes in benign and malignant diseases. Surg. Gynecol. Obstet., 144: 435-450, 1977.
16. Domagala, W., Emeson, E. E., and Koss, L. G. Distribution of T-lymphocytes and B lymphocytes in a peripheral blood and effusions of patients with cancer. J. Natl. Cancer Inst., 61: 295-300, 1978.
17. Wood, G. W., and Neff, J. R. A reevaluation of B lymphocyte levels in peripheral blood from cancer patients. J. Natl. Cancer Inst., 61: 715-718, 1978.
18. Kay, N. E., Leong, T., Kyle, R. A., Greipp, P., Billadeau, D., Van Ness, B., Bone, N., and Oken, M. M. Circulating blood B cells in multiple myeloma: analysis and relationship to circulating clonal cells and clinical parameters in a cohort of patients entered on the eastern cooperative oncology group Phase III E9486 clinical trail. Blood, 90: 340-345, 1997.
19. Rawstron, A. C., Davies, F. E., Owen, R. G., English, A., Pratt, G., Child, J. A., Jack, A. S., and Morgan, G. J. B lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B-cell progenitors and plasma cell precursors. Br. J. Haematol., 100: 176-183, 1998.
20. Stein, R., Witz, I. P., Ovadia, J., Goldenberg, D. M., and Yron, I. CD5+ B cells and naturally occurring autoantibodies in cancer patients. Clin. Exp. Immunol., 85: 418-423, 1991.